1. Home
  2. SW vs RPRX Comparison

SW vs RPRX Comparison

Compare SW & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smurfit WestRock plc Ordinary Shares

SW

Smurfit WestRock plc Ordinary Shares

HOLD

Current Price

$41.42

Market Cap

20.3B

Sector

N/A

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$48.65

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SW
RPRX
Founded
1934
1996
Country
Ireland
United States
Employees
97000
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3B
19.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SW
RPRX
Price
$41.42
$48.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
4
Target Price
$53.25
$50.00
AVG Volume (30 Days)
4.6M
2.8M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.30%
1.93%
EPS Growth
N/A
N/A
EPS
N/A
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$4.50
$38.30
Revenue Next Year
$3.10
$4.80
P/E Ratio
$38.98
$27.41
Revenue Growth
N/A
5.06
52 Week Low
$32.73
$31.58
52 Week High
$52.65
$49.06

Technical Indicators

Market Signals
Indicator
SW
RPRX
Relative Strength Index (RSI) 49.66 63.13
Support Level $40.97 $35.32
Resistance Level $44.44 $49.06
Average True Range (ATR) 1.12 0.90
MACD 0.43 0.07
Stochastic Oscillator 59.89 89.00

Price Performance

Historical Comparison
SW
RPRX

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: